REVIEW OF THE MARKET OF MEDICINAL PRODUCTS FOR THE TREATMENT OF RESPIRATORY DISEASES WITH IMMUNOMODULATORY AND/OR ANTIVIRAL EFFECT IN THE RETAIL COMMERCIAL SECTOR OF THE PHARMACEUTICAL MARKET BASED ON THE RESULTS OF 2016
Based on the results of 2016, the available retail commercial market for the products with immunomodulatory and/or antiviral effect [1] used for prevention and treatment of respiratory diseases reached 31.82 billion rubles [2] by value and 98.61 million packages by volume, showing a solid increase in sales of 21 and 12% respectively (Figure 1).
[1] The review includes the medicinal products with immunomodulatory and/or antiviral effect used for the treatment of respiratory diseases (by EphMRA classification): A13A restoratives, J5B4 antiviral drugs for the treatment of influenza, J5B9 other antiviral drugs, L3A9 other immunostimulants excluding interferons, L3B1 interferon-alpha (excluding homeopathic products and products of vegetable and bacterial origin). The indications for their use are posed on the website of the State register of medicinal products and feature their use for the prevention or treatment of respiratory diseases (expert sample). The brand Reaferon includes only capsules and lyophilizate for the preparation of suspension; Genferon is presented as a spray; Galavit includes suppositories and tablets; Cycloferon is presented as tablets; Derinat is a solution for topical application; Timogen is a spray.
[2] According to the information on retail sales from pharmacies (sell-out prices).
Based on the results of 2016, the available retail commercial market for the products with immunomodulatory and/or antiviral effect [1] used for prevention and treatment of respiratory diseases reached 31.82 billion rubles [2] by value and 98.61 million packages by volume, showing a solid increase in sales of 21 and 12% respectively (Figure 1).
[1] The review includes the medicinal products with immunomodulatory and/or antiviral effect used for the treatment of respiratory diseases (by EphMRA classification): A13A restoratives, J5B4 antiviral drugs for the treatment of influenza, J5B9 other antiviral drugs, L3A9 other immunostimulants excluding interferons, L3B1 interferon-alpha (excluding homeopathic products and products of vegetable and bacterial origin). The indications for their use are posed on the website of the State register of medicinal products and feature their use for the prevention or treatment of respiratory diseases (expert sample). The brand Reaferon includes only capsules and lyophilizate for the preparation of suspension; Genferon is presented as a spray; Galavit includes suppositories and tablets; Cycloferon is presented as tablets; Derinat is a solution for topical application; Timogen is a spray.
[2] According to the information on retail sales from pharmacies (sell-out prices).
The reproduction of materials is allowed only if the limitations established by the Rightholder are observed, with mention of the author of the materials used and the reference to ALPHARM LLC as a source, with a mandatory hyperlink to www.alpharm.ru website.